NextCure and Avere to merge, targeting oral IL-23 therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
July 14, 2026 6:00 AM EDTAvere Therapeutics lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once-weekly oral therapy
Concurrent $320 million private investment from world-class investor syndicate ensures combined company is well-capitalized to accelerate development of AVR-001
Companys financial runway expected to fund AVR-001 through Phase 2b readout in psoriasis, initiation of a Phase 3 trial in psoriasis, and initiation of a Phase 2b trial in ulcerative colitis
... More